"limited pipeline after E and VMAT 2"? Have you forgotten about the two novel compounds for novel indications that are working their way through the "gauntlet"? ;-))))
I like your buyout target of $50, but I think Kevy is bent on keeping VMAT2 in the US as his rice bowl.
Elagolix is an exciting compound that seems to be superior to the current therapy, particularly in an oral tablet. The pharmacological mechanism of this pill is very clear and predictable. There are some confusion to me when Abbvie will report P3 results on Elagolix. And will Abbvie report the full results or just the top line data? If you could share the information, I would greatly appreciate. Go NBIX
The stock does want to go to $20+ PPS Before E P3 Results.
Positive trial results we head towards $30 as Abbvie will buy out NBIX north of $50
No reason for NBIX to be a stand alone biotech given its limited pipeline after E and VMAT2
Sentiment: Strong Buy
Answer: (1) They have been in business for 21 years plus. (2) They have never produced a commercial product. (3) They have survived on multiple secondary offerings and payments from pharma partners. Will they ever make money? I say yes. The partnership with Abbvie calls for substantial royalties from Elagolix which is in Phase III testing. VMAT2 is about to enter Phase III, so it is also late stage. Short at your own considerable risk, IMO.
yes. my target is still $0. how long have they been in business? how much profit have they made? they will never make money. just another wall street overhyped PIG.
Revenues driven by recent contracts for the most advanced life saving diagnostics will expand 150 times in the next 24 months. And that is just the beginning!
Millennium Healthcare (MHCC) recently announced newly SIGNED contracts with ACO’s IPA’s and MSO’s to provide exclusive, state-of-the-art, non-invasive cardiovascular and cancer diagnostics to 1,300 locations that will escalate Millennium’s current revenues of $2 million per year to over $300 million per year.
Cardiovascular and cancer diagnostics rolling out to physician’s offices this year.
Revenues will begin rapid growth by year end.
Market size for Millennium Diagnostics is 35,000 primary care offices. The first 1,300 recently contracted with Millennium and the rest are standing in line to sign up with Millennium because:
§ Millenniums program increases physician’s revenues dramatically
§ Millennium’s diagnostics are fully paid by Medicare and are free to patients
§ Millennium’s diagnostics appeal to patients because they are life-saving, fast, painless and highly accurate
§ Millennium’s diagnostics are exclusive from Millennium only
§ The physician pays no up front capital costs
Millennium’s market cap is under $40 million today and shares are selling at under $1.00.
What will this growth do to the price of MHCC shares?
Millennium HealthCare is well positioned for explosive growth that is rarely seen.
Sentiment: Strong Buy
I always wondered what fix was in w/the FDA on that one. Meanwhile, aside from elagolix, all the implosions since then have been mgt arson.